Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

real-time data

- PMLiVE

Being the change

Why it’s better to enable the future than to fight it

- PMLiVE

The Power of Strong Partnerships

The Bedrock team reflects on what is critical to building strong partnerships.

Resonant Group

- PMLiVE

Pfizer’s maternal RSV vaccine granted FDA approval to protect infants

The decision allows Abrysvo to be given to those who are 32 to 36 weeks into their pregnancy

- PMLiVE

Janssen’s Tecvayli approved by EC for reduced dosing frequency in multiple myeloma

Tecvayli was the first BCMA-targeting bispecific antibody to be approved in Europe

- PMLiVE

Boehringer sues US government over Medicare drug price negotiation programme

The IRA allows Medicare to negotiate lower prices for selected medicines

- PMLiVE

The rise of biologics: is the sector ready for future demand?

Looking at the evolving biological sector and the various capacity challenges that global biopharma companies will have to bridge

- PMLiVE

Medscape Education Launches 20th Older Driver Safety Educational Program

Education Supported by the National Highway Traffic Safety Administration

Medscape Education

regeneron headquarters

Regeneron’s Veopoz granted FDA approval for ultra-rare immune disease

Fewer than ten patients in the US have been diagnosed with CHAPLE disease

- PMLiVE

Merck shares positive late-stage results for Welireg in advanced kidney cancer

Renal cell carcinoma accounts for approximately 90% of kidney cancer diagnoses

- PMLiVE

Research shows new scientific technique could halve polio detection times

The new method could reduce costs and detection times for public health authorities

- PMLiVE

NICE recommends Amryt’s Filsuvez treatment for epidermolysis bullosa

Approximately 670 people in England are expected to benefit from the skin-wound-healing treatment

Tooth and nail

With Merck and BMS first out of the gates, here comes the assault on the Inflation Reduction Act

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links